Dias J, Granja PL*, Bártolo PJ*. Prog Mater Sci 2016;84:314-34. * Equal contribution
Silva ED, Babo PS, Costa-Almeida R, Domingues RMA, Mendes BB, Paz E, Freitas P, Rodrigues MT, Granja PL, Gomes ME. Nanomedicine 2018;14:2375-85.
Araújo F, das Neves J, Martins JP, Granja PL, Santos HA, Sarmento B. Progr Mater Sci 2017;89:306-44.
Neves MI, Wechsler ME, Gomes ME, Reis RL, Granja PL*, Peppas NA*. Tissue Eng B Rev 2017;23:27-43. * Equal contribution
Pereira RF, Sousa A, Barrias CC, Granja PL, Bártolo PJ. Biomanuf Rev 2017;2:1.
The Biomaterials Network (Biomat.net) was published online in February 2, 1998. We’re proud of serving our community for 19 years – a very long time for an internet portal.
Raquel Costa-Almeida, Raquel Soares and Pedro L. Granja. J Tissue Eng Regen Med 2018;12:240-51.
Fibroblasts constitute a dynamic and versatile population of cells of mesenchymal origin, implicated in both regenerative strategies and pathological conditions. Despite being frequently associated to disease development, particularly through the establishment of fibrotic tissue, fibroblasts hold great potential for tissue engineering and regenerative medicine applications. They are responsible for synthesizing and depositing extracellular matrix components, allowing other cells to settle and migrate along a three-dimensional support and thereby generating an organ-specific architecture. Additionally, they produce bioactive molecules that are involved in several physiological processes, including angiogenesis and tissue repair. Although there seems to be much still to unveil about these fascinating cells they have been attracting increasing interest and are now being intensively explored as a cell source to develop bioengineered tissue constructs or to improve stem cell-based technologies. This review intends to highlight the potential of fibroblasts in orchestrating tissue regeneration, as well as to contribute to uncover uncharted prospective applications of these cells.